Doing business for over a decade as Yaupon Therapeutics, Inc, primarily organized around IP licensed from the University of Kentucky, the firm has been working on utilizing transdermal delivery technology to deliver S-(-)-nornicotine through skin for the treatment of nicotine dependence. Plants had for centuries been known a repository of naturally occurring compounds to treat disease. Yaupon was applying modern techniques to identify valuable medicines that address unmet medical needs. In January 2012, the firm changed its name to Ceptaris Therapeutics Inc. and shifted focus to development of mechlorethamine gels using a formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. By September 2013, Ceptaris Therapeutics Inc. was acquired and operates as a subsidiary of Actelion US Holding Company.
